Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer

Biomaterials

Volumn 104, Issue , 2016, Pages 339-351

  Lin, Tzu Yin ^a   Li, Yuanpei ^a   Liu, Qiangqiang ^a   Chen, Jui Lin ^b   Zhang, Hongyong ^a   Lac, Diana ^a   Zhang, Hua ^c   Ferrara, Katherine W ^c   Wachsmann Hogiu, Sebastian ^d   Li, Tianhong ^a,e   Airhart, Susan ^f   deVere White, Ralph ^d   Lam, Kit S ^a   Pan, Chong Xian ^a,d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c University of California Davis   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^f JACKSON LABORATORY   (United States)

Author keywords

Bladder cancer; Nanotechnology; Photodynamic therapy; Photothermal therapy

Indexed keywords

CHEMOTHERAPY; DIAGNOSIS; DISEASES; FLUORESCENCE; INFRARED DEVICES; NANOTECHNOLOGY;

5-AMINOLEVULINIC ACID; BLADDER CANCER CELLS; BLADDER CANCERS; FLUORESCENCE SIGNALS; PHOTO DYNAMIC DIAGNOSIS; PHOTOTHERMAL THERAPY; SYSTEMIC CIRCULATION; TARGETED CHEMOTHERAPY;

PHOTODYNAMIC THERAPY;

AMINOLEVULINIC ACID; CASPASE 3; CASPASE 7; DOXORUBICIN; NANOPORPHYRIN; PORPHYRIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; NANOPARTICLE; PHOTOSENSITIZING AGENT; PLZ4 PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED RADIATION; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SYSTEMIC CIRCULATION; THERANOSTIC NANOMEDICINE; ANIMAL; BLADDER TUMOR; C57BL MOUSE; CHEMISTRY; FLUORESCENCE MICROSCOPY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOXORUBICIN; HUMANS; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; PEPTIDES, CYCLIC; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PHOTOTHERAPY; PORPHYRINS; THERANOSTIC NANOMEDICINE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84979747678     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.07.026     Document Type: Article

References (51)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30.
2. [2] Herr, H.W., Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J. Urol. 174 (2005), 2134–2137.
3. [3] Chamie, K., Litwin, M.S., Bassett, J.C., Daskivich, T.J., Lai, J., Hanley, J.M., et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer 119 (2013), 3219–3227.
4. [4] Botteman, M.F., Pashos, C.L., Redaelli, A., Laskin, B., Hauser, R., The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEconomics 21 (2003), 1315–1330.
5. [5] Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012. CA Cancer J. Clin. 62 (2012), 10–29.
6. [6] Ray, E.R., Chatterton, K., Thomas, K., Khan, M.S., Chandra, A., O'Brien, T.S., Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer. J. Endourol. Endourol. Soc. 23 (2009), 983–988.
7. [7] Kausch, I., Sommerauer, M., Montorsi, F., Stenzl, A., Jacqmin, D., Jichlinski, P., et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur. Urol. 57 (2010), 595–606.
8. [8] Burger, M., Grossman, H.B., Droller, M., Schmidbauer, J., Hermann, G., Dragoescu, O., et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur. Urol. 64 (2013), 846–854.
9. [9] Manyak, M.J., Ogan, K., Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium. J. Endourol. Endourol. Soc. 17 (2003), 633–639.
10. [10] Agostinis, P., Berg, K., Cengel, K.A., Foster, T.H., Girotti, A.W., Gollnick, S.O., et al. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 61 (2011), 250–281.
11. [11] Mariappan, P., Rai, B., El-Mokadem, I., Anderson, C.H., Lee, H., Stewart, S., et al. Real-life experience: early recurrence with hexvix photodynamic diagnosis-assisted transurethral resection of bladder tumour vs good-quality white light TURBT in new non-muscle-invasive bladder cancer. Urology 86 (2015), 327–331.
12. [12] Lykke, M.R., Nielsen, T.K., Ebbensgaard, N.A., Zieger, K., Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis. Scand. J. Urol. 49 (2015), 230–236.
13. [13] Inoue, K., Fukuhara, H., Shimamoto, T., Kamada, M., Iiyama, T., Miyamura, M., et al. Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer. Cancer 118 (2012), 1062–1074.
14. [14] Mowatt, G., N'Dow, J., Vale, L., Nabi, G., Boachie, C., Cook, J.A., et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int. J. Technol. Assess. Health Care 27 (2011), 3–10.
15. [15] Chin, W.W.L., Lau, W.K.O., Heng, P.W.S., Bhuvaneswari, R., Olivo, M., Fluorescence imaging and phototoxicity effects of new formulation of chlorin e6-polyvinylpyrrolidone. J. Photochem. Photobiol. B 84 (2006), 103–110.
16. [16] Bellnier, D.A., Henderson, B.W., Pandey, R.K., Potter, W.R., Dougherty, T.J., Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-Hexyloxyethyl]-2-Devinyl pyropheophorbide-a. J. Photoch Photobiol. B 20 (1993), 55–61.
17. [17] Inoue, K., Anai, S., Fujimoto, K., Hirao, Y., Furuse, H., Kai, F., et al. Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: a randomized, double-blind, multicentre phase II/III study. Photodiagnosis Photodyn. Ther. 12 (2015), 193–200.
18. [18] Ballut, S., Makky, A., Loock, B., Michel, J.P., Maillard, P., Rosilio, V., New strategy for targeting of photosensitizers. Synthesis of glycodendrimeric phenylporphyrins, incorporation into a liposome membrane and interaction with a specific lectin. Chem. Commun. (Camb), 2009, 224–226.
19. [19] Li, Y., T-y, Lin, Luo, Y., Liu, Q., Xiao, W., Guo, W., et al. A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nat. Commun., 5, 2014.
20. [20] Zhang, H., Aina, O.H., Lam, K.S., de Vere White, R., Evans, C., Henderson, P., et al. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol. Oncol. 30:5 (2012), 635–645.
21. [21] Lin, T.Y., Zhang, H., Wang, S., Xie, L., Li, B., Rodriguez, C.O. Jr., et al. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol. Cancer, 10, 2011, 9.
22. [22] Lin, T.Y., Li, Y.P., Zhang, H., Luo, J., Goodwin, N., Gao, T., et al. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine 8 (2013), 1239–1251.
23. [23] Luo, J., Xiao, K., Li, Y., Lee, J.S., Shi, L., Tan, Y.H., et al. Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjugate Chem. 21 (2010), 1216–1224.
24. [24] Peng, L.L.R., Marik, J., Wang, X., Takada, Y., Lam, K.S., Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4 beta1 integrin. Nat. Chem. Biol. 2 (2006), 381–389.
25. [25] Xiao, W., Wang, Y., Lau, E.Y., Luo, J., Yao, N., Shi, C., et al. The use of one-bead one-compound combinatorial library technology to discover high-affinity alphavbeta3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. Mol. Cancer Ther. 9 (2010), 2714–2723.
26. [26] Ostaci, R.V., Damiron, D., Grohens, Y., Leger, L., Drockenmuller, E., Click chemistry grafting of poly(ethylene glycol) brushes to alkyne-functionalized pseudobrushes. Langmuir 26 (2010), 1304–1310.
27. [27] Xiao, K., Li, Y., Lee, J.S., Gonik, A.M., Dong, T., Fung, G., et al. “OA02” peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res. 72 (2012), 2100–2110.
28. [28] Lin, T.Y., Zhang, H., Luo, J., Li, Y., Gao, T., Lara, P.N. Jr., et al. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int. J. Nanomed. 7 (2012), 2793–2804.
29. [29] Xiao, K., Li, Y., Luo, J., Lee, J.S., Xiao, W., Gonik, A.M., et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32 (2011), 3435–3446.
30. [30] Yang, X.H., Ren, L.S., Wang, G.P., Zhao, L.L., Zhang, H., Mi, Z.G., et al. A new method of establishing orthotopic bladder transplantable tumor in mice. Cancer Biol. Med. 9 (2012), 261–265.
31. [31] Pan, C.X., Zhang, H., Tepper, C.G., Lin, T.Y., Davis, R.R., Keck, J., et al. Development and characterization of bladder cancer patient-derived xenografts for molecularly guided targeted therapy. PloS One, 10, 2015, e0134346.
32. [32] Nargund, V.H., Tanabalan, C.K., Kabir, M.N., Management of non-muscle-invasive (superficial) bladder cancer. Seminars Oncol. 39 (2012), 559–572.
33. [33] Guelluy, P.H., Fontaine-Aupart, M.P., Grammenos, A., Lecart, S., Piette, J., Hoebeke, M., Optimizing photodynamic therapy by liposomal formulation of the photosensitizer pyropheophorbide-a methyl ester: in vitro and ex vivo comparative biophysical investigations in a colon carcinoma cell line. Photochem. Photobiol. Sci. Off. J. Eur. Photochem. Assoc. Eur. Soc. Photobiol. 9 (2010), 1252–1260.
34. [34] Zhu, Y., Liu, C., Nadiminty, N., Lou, W., Tummala, R., Evans, C.P., et al. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol. Cancer Ther. 12 (2013), 1829–1836.
35. [35] Lovell, J.F., Jin, C.S., Huynh, E., Jin, H., Kim, C., Rubinstein, J.L., et al. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat. Mater. 10 (2011), 324–332.
36. [36] Jin, C.S., Cui, L., Wang, F., Chen, J., Zheng, G., Targeting-triggered porphysome nanostructure disruption for activatable photodynamic therapy. Adv. Healthc. Mater. 3:8 (2014), 1240–1249.
37. [37] Li, Y., Xiao, K., Luo, J., Lee, J., Pan, S., Lam, K.S., A novel size-tunable nanocarrier system for targeted anticancer drug delivery. J. Control. release Off. J. Control. Release Soc. 144 (2010), 314–323.
38. [38] Waters, W.B., Herbster, G., Jablokow, V.R., Reda, D.J., Ureteral replacement using ileum in compromised renal function. J. urology 141 (1989), 432–436.
39. [39] Cookson, M.S., Herr, H.W., Zhang, Z.F., Soloway, S., Sogani, P.C., Fair, W.R., The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. urology 158 (1997), 62–67.
40. [40] Herr, H.W., Schwalb, D.M., Zhang, Z.F., Sogani, P.C., Fair, W.R., Whitmore, W.F. Jr., et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 13 (1995), 1404–1408.
41. [41] Colleselli, D., Stenzl, A., Schwentner, C., Jentzmik, Florian, Stephan, Carsten, Miller, Kurt, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur. Urol. 58 (2010), 12–18 Eur Urol. 2010;58:e51.
42. [42] Denzinger, S., Burger, M., Walter, B., Knuechel, R., Roessler, W., Wieland, W.F., et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69 (2007), 675–679.
43. [43] Schumacher, M.C., Holmang, S., Davidsson, T., Friedrich, B., Pedersen, J., Wiklund, N.P., Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur. Urol. 57 (2010), 293–299.
44. [44] Seidl, J., Rauch, J., Krieg, R.C., Appel, S., Baumgartner, R., Knuechel, R., Optimization of differential photodynamic effectiveness between normal and tumor urothelial cells using 5-aminolevulinic acid-induced protoporphyrin IX as sensitizer. Int. J. cancer J. Int. du cancer 92 (2001), 671–677.
45. [45] Sano, K., Nakajima, T., Choyke, P.L., Kobayashi, H., Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano 7 (2013), 717–724.
46. [46] Snyder, J.W., Greco, W.R., Bellnier, D.A., Vaughan, L., Henderson, B.W., Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res. 63 (2003), 8126–8131.
47. [47] Luo, D., Carter, K.A., Razi, A., Geng, J., Shao, S., Giraldo, D., et al. Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release. Biomaterials 75 (2016), 193–202.
48. [48] Zhen, Z., Tang, W., Guo, C., Chen, H., Lin, X., Liu, G., et al. Ferritin nanocages to encapsulate and deliver photosensitizers for efficient photodynamic therapy against cancer. ACS Nano 7 (2013), 6988–6996.
49. [49] Luo, D., Carter, K.A., Miranda, D., Lovell, J.F., Chemophototherapy: an emerging treatment option for solid tumors. Adv. Sci., 2016 (n/a-n/a).
50. [50] Nava, H.R., Allamaneni, S.S., Dougherty, T.J., Cooper, M.T., Tan, W., Wilding, G., et al. Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus. Lasers Surg. Med. 43 (2011), 705–712.
51. [51] Dhillon, S.S., Demmy, T.L., Yendamuri, S., Loewen, G., Nwogu, C., Cooper, M., et al. A phase I study of light dose for photodynamic therapy using 2-[1-Hexyloxyethyl]-2 devinyl pyropheophorbide-a for the treatment of non-small cell carcinoma in situ or non-small cell microinvasive bronchogenic carcinoma: a dose ranging study. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 11 (2016), 234–241.